Preliminary results from two early-phase clinical trials suggest that the investigational drug ibrutinib may benefit some patients with an aggressive type of non-Hodgkin lymphoma (NHL). The treatment was well tolerated,… Read more »
Preliminary results from two early-phase clinical trials suggest that the investigational drug ibrutinib may benefit some patients with an aggressive type of non-Hodgkin lymphoma (NHL). The treatment was well tolerated,… Read more »
April will be a busy month, so make sure these dates are on your calendar: Spirituality & End-of-Life Care, a free program for professionals, co-sponsored by Cancer Services & Dignity… Read more »
“Non-Hodgkin’s Lymphoma: From Diagnosis to Treatment and Beyond” A collaboration between Cancer Services and The Leukemia & Lymphoma Society. Presented by Dr. David Zimmerman, Fort Wayne Medical Oncology and Hematology… Read more »
